ArticleNature communications2025

Targeting Msx2 as a brake in the fusion fate of osteoclasts and an anabolic therapy in pre-clinical models of osteoporosis.

Qingliang Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.